The AACR meeting was full of promising data on the vaccine against cervical cancer, a lung cancer drug and the next generation of KRAS inhibitors.

A vaccine that blocks infection with the human papillomavirus has helped to lower cervical cancer rates. Researchers want to ...

Worldwide, 350,000 women die from cervical cancer, the most common HPV cancer. “I think we can all agree that one dose and two doses of … these fantastic vaccines work really well,” said ...

One dose of a human papillomavirus (HPV) vaccine was noninferior to two doses in preventing infection, data from a randomized trial showed. In the ESCUDDO trial, which involved more than 20,000 ...

Safety documentation is a priority in all phases of the vaccine clinical trials. Safety is categorized as local reactions from the injection itself and as systemic reactions that may occur ...

Wayne Griffiths said his wished the HPV vaccine was available when his daughter Rhian was a child The family of a 25-year-old who died from cervical cancer after contracting human papillomavirus ...

Vaccines that protect against the types of human papillomavirus (HPV) most commonly associated with squamous cell cervical carcinoma are nearing approval in the U.S. But how long will these ...

While HHS Secretary Kennedy frets over food dye in Froot Loops, his 2023 attack on Gardasil — a vaccine proven to prevent ...

Nearly all newborns who contract human papillomavirus in the perinatal stage will eliminate the virus in the first six months ...

SEATTLE — Since its approval by the U.S. Food and Drug Administration in 2006, the HPV vaccine has made considerable strides in preventing cervical and oropharyngeal, or throat cancers.

However, cervical cancer screening remains lower than pre-pandemic levels, and the HPV vaccination rate has not increased since the pandemic, researchers found. Other major cancer risk factors ...